Atopic - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Future of IL-33 inhibition in atopic dermatitis in doubt

Atopic
AnaptysBio’s etokimab failed to meet its primary endpoint in a Phase IIb study.